Actively Recruiting
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Led by Institute of Liver and Biliary Sciences, India · Updated on 2025-08-13
132
Participants Needed
1
Research Sites
852 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Patients of cirrhosis aged 18 to 75 years who have no esophageal varices will be enrolled. After baseline evaluation, the participants will be randomized to receive either Placebo or Carvedilol 12.5 mg BD. After randomization they will be followed up for one year.
CONDITIONS
Official Title
Carvedilol for Pre-primary Prophylaxis of Esophageal Varices in Cirrhosis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients of cirrhosis aged 18 to 75 years who have no esophageal or gastric varices.
You will not qualify if you...
- Any contra-indication to beta-blockers
- Any past EVL or sclerotherapy
- Any past history of surgery for portal hypertension
- Significant cardio or pulmonary co-morbidity
- Any malignancy
- Refusal to participate in the study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Institute of Liver & Biliary Sciences (ILBS)
New Delhi, National Capital Territory of Delhi, India
Actively Recruiting
Research Team
D
Dr Ankur Jindal, DM
CONTACT
D
Dr Ankit Bhardwaj, PhD (Epidemiology)
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here